FierceBiotech: MorphoSys fails secondary in blood cancer trial, sinking stock

Thread starter anonymous
Start date Nov 21, 2023
Tags

None

Quote

anonymous

Guest

anonymous Nov 21, 2023 at 05:45: PM

#1

anonymous

Guest

MorphoSys CEO eats own words after mixed trial results

MorphoSys, after saying AbbVie 'failed,' defends own mixed blood cancer data, plots approval filings

anonymous

Guest

anonymous Nov 22, 2023 at 12:52: PM

#2

anonymous

Guest

Welcome to the goat rodeo.

Name

Share:

Facebook Twitter Reddit Pinterest Tumblr WhatsApp Email Link

Top Bottom

Back

Quote